Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study

被引：6

作者：

Sgouros J. ^{[1
]}

Aravantinos G. ^{[2
]}

Kouvatseas G. ^{[3
]}

Rapti A. ^{[1
]}

Stamoulis G. ^{[1
]}

Bisvikis A. ^{[1
]}

Res H. ^{[1
]}

Samantas E. ^{[1
]}

机构：

[1] 3rd Medical Oncology Department, “Agii Anargiri” General Cancer Hospital, Kaliftaki, N. Kifissia

[2] 2nd Medical Oncology Department, “Agii Anargiri” General Cancer Hospital, Kaliftaki, N. Kifissia

[3] Health Data Specialists, Ltd, 22 Katehaki Str, Athens

来源：

Journal of Gastrointestinal Cancer | 2015年 / 46卷 / 4期

关键词：

Adjuvant chemotherapy; Colorectal cancer; Delays between chemotherapy cycles; Dose reductions; Omission of chemotherapy cycles;

D O I：

10.1007/s12029-015-9746-8

中图分类号：

学科分类号：

摘要：

Purpose: Most stage II or III colorectal cancer patients are receiving nowadays a 4 to 6-month course of adjuvant chemotherapy. However, delays between cycles, reductions in the doses of chemotherapy drugs, or even permanent omissions of chemotherapy cycles might take place due to side effects or patient’s preference. We examined the impact of these treatment modifications on recurrence-free survival (RFS) and overall survival (OS). Methods: We retrospectively collected data from colorectal cancer patients who had received adjuvant chemotherapy in our Department. Patients were categorized in five groups based on whether they had or not delays between chemotherapy cycles, dose reductions, and permanent omissions of chemotherapy cycles. Three-year RFS and OS of the five different groups were compared using the log-rank test and the Sidak approach. Results: Five hundred and eight patients received treatment. Twenty seven percent of the patients had the full course of chemotherapy; the others had delays, dose reductions, or early termination of the treatment. No statistically significant differences were observed in 3-year RFS and OS between the five groups. A trend for worse RFS was noticed with early termination of treatment. A similar trend was also noticed for OS but only for stage II patients. Conclusion: In colorectal cancer patients, receiving adjuvant chemotherapy, delays between chemotherapy cycles, dose reductions of chemotherapy drugs, or even early termination of the treatment course do not seem to have a negative impact in 3-year RFS and OS; however, due to the trend of worse RFS in patients receiving shorter courses of chemotherapy, further studies are needed. © 2015, Springer Science+Business Media New York.

引用

页码：343 / 349

页数：6

共 23 条

[11] Smoragiewicz M., Javaheri K.R., Yin Y., Gill S., Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer, J Gastrointest Cancer, 45, pp. 460-465, (2014)
[12] Aspinall S.L., Good C.B., Zhao X., Cunningham F.E., Heron B.B., Geraci M., Et al., Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans, BMC Cancer, 15, (2015)
[13] Chau I., Norman A.R., Cunningham D., Tait D., Ross P.J., Iveson T., Et al., A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer, Ann Oncol, 16, pp. 549-557, (2005)
[14] Peto R., Peto J., Asymptotically efficient rank invariant test procedures, J R Stat Soc A, 135, pp. 185-198, (1972)
[15] Sidak Z.K., Rectangular confidence regions for the means of multivariate normal distributions, J Am Stat Assoc, 62, pp. 626-633, (1967)
[16] Kaplan E., Meier P., Non parametric estimation from incomplete observations, J Am Stat Assoc, 53, pp. 457-481, (1958)
[17] Papadimitriou C.A., Papakostas P., Karina M., Malettou L., Dimopoulos M.A., Pentheroudakis G., Et al., A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study, BMC Med, 9, (2011)
[18] Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Et al., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 350, pp. 2343-2351, (2004)
[19] Abrams T.A., Brightly R., Mao J., Kirkner G., Meyerhardt J.A., Schrag D., Et al., Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer, J Clin Oncol, 29, pp. 3255-3262, (2011)
[20] Ho J., Gill S., Woods R., Kennecke H.F., Association of survival outcomes with dose intensity of adjuvant therapy with capecitabine for colorectal cancer, J Clin Oncol, 28, (2010)

← 1 2 3 →